SG11201707683YA - C/ebp alpha sarna compositions and methods of use - Google Patents

C/ebp alpha sarna compositions and methods of use

Info

Publication number
SG11201707683YA
SG11201707683YA SG11201707683YA SG11201707683YA SG11201707683YA SG 11201707683Y A SG11201707683Y A SG 11201707683YA SG 11201707683Y A SG11201707683Y A SG 11201707683YA SG 11201707683Y A SG11201707683Y A SG 11201707683YA SG 11201707683Y A SG11201707683Y A SG 11201707683YA
Authority
SG
Singapore
Prior art keywords
methods
ebp alpha
sarna compositions
compositions
alpha sarna
Prior art date
Application number
SG11201707683YA
Inventor
Andreas Wagner
Robert Habib
Hans E Huber
Pål Saetrom
Endre Bakken Stovner
Markus Hossbach
Monika Krampert
Hans-Peter Vornlocher
Original Assignee
Mina Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mina Therapeutics Ltd filed Critical Mina Therapeutics Ltd
Publication of SG11201707683YA publication Critical patent/SG11201707683YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/113Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3222'-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/352Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521Methyl
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/353Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533Halogen
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201707683YA 2015-04-22 2016-04-21 C/ebp alpha sarna compositions and methods of use SG11201707683YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562150889P 2015-04-22 2015-04-22
US201562235778P 2015-10-01 2015-10-01
US201662308521P 2016-03-15 2016-03-15
PCT/GB2016/051117 WO2016170349A1 (en) 2015-04-22 2016-04-21 C/ebp alpha sarna compositions and methods of use

Publications (1)

Publication Number Publication Date
SG11201707683YA true SG11201707683YA (en) 2017-11-29

Family

ID=55948895

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201707683YA SG11201707683YA (en) 2015-04-22 2016-04-21 C/ebp alpha sarna compositions and methods of use

Country Status (9)

Country Link
US (2) US10912790B2 (en)
EP (1) EP3286316A1 (en)
JP (4) JP6768701B2 (en)
KR (2) KR102599712B1 (en)
CN (2) CN114525279A (en)
AU (3) AU2016251415B9 (en)
CA (1) CA2980975A1 (en)
SG (1) SG11201707683YA (en)
WO (1) WO2016170349A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3236835A1 (en) * 2013-11-22 2015-05-28 Mina Therapeutics Limited C/ebp alpha short activating rna compositions and methods of use
WO2018104538A1 (en) * 2016-12-08 2018-06-14 Curevac Ag Rna for treatment or prophylaxis of a liver disease
CA3075205A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
US20200208152A1 (en) * 2017-09-08 2020-07-02 Mina Therapeutics Limited Stabilized sarna compositions and methods of use
CN108103108A (en) * 2018-01-30 2018-06-01 上海交通大学医学院附属瑞金医院 Preparation and application of Cebpa gene-deleted zebra fish mutant
US20210024928A1 (en) * 2018-02-16 2021-01-28 Mina Therapeutics Limited C/ebp alpha sarna compositions and methods of use
EP3778892A4 (en) * 2018-04-10 2022-01-19 Ractigen Therapeutics Novel small activating rna
WO2019239144A1 (en) 2018-06-15 2019-12-19 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna
CN114585384A (en) * 2019-07-26 2022-06-03 米纳治疗有限公司 Compositions and methods using C/EBP alpha sarRNA
EP4069848A4 (en) * 2019-12-03 2024-02-28 Merck Sharp & Dohme LLC In vitro cell based potency assay
GB202019692D0 (en) * 2020-12-14 2021-01-27 Apterna Ltd Aptamer-sirna fusions
EP4329777A1 (en) 2021-04-28 2024-03-06 MiNA Therapeutics Limited Combination therapies comprising c/ebp alpha sarna
KR102428121B1 (en) * 2021-10-20 2022-08-08 주식회사 네오나 Delivery system for preventing or treating of liver cancer comprising modified rt-let7 as an active ingredient
CN114306367B (en) * 2021-08-27 2023-03-28 赵小洋 Composition containing C/EBP alpha-saRNA
US20240207204A1 (en) * 2022-12-12 2024-06-27 Regeneron Pharmaceuticals, Inc. Treatment Of Type 2 Diabetes With Hepatocyte Nuclear Factor 4 Alpha (HNF4A) Agonists
WO2024134199A1 (en) * 2022-12-22 2024-06-27 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use
WO2024165876A2 (en) * 2023-02-10 2024-08-15 Mina Therapeutics Limited Compositions and methods of using c/ebp alpha sarna
WO2024175887A1 (en) 2023-02-22 2024-08-29 Mina Therapeutics Limited Compositions and methods of using c/ebp alpha sarna
KR20240138691A (en) * 2023-03-13 2024-09-20 부산대학교 산학협력단 Biomarker composition for diagnosing rheumatoid arthritis, diagnostic kit using the same, and method for diagnosing rheumatoid arthritis using the same
CN118480552B (en) * 2024-01-18 2024-10-01 成都先衍生物技术有限公司 SARNA for targeting CEBPA gene expression and application thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2990410A1 (en) * 2004-08-10 2016-03-02 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
CA2743074A1 (en) * 2008-11-13 2010-05-20 Erasmus University Medical Center Rotterdam Efficient detection of double mutants of the cebpa gene in aml.
CN102612560B (en) * 2009-06-16 2017-10-17 库尔纳公司 By suppressing to treat the related diseases of PON1 for the natural antisense transcript of PON1 (PON1)
GB201010557D0 (en) * 2010-06-23 2010-08-11 Mina Therapeutics Ltd RNA molecules and uses thereof
EP3702460A1 (en) * 2010-11-12 2020-09-02 The General Hospital Corporation Polycomb-associated non-coding rnas
WO2012175958A1 (en) * 2011-06-21 2012-12-27 Mina Therapeutics Limited Albumin production and cell proliferation
DE102011079572A1 (en) * 2011-07-21 2013-01-24 Endress + Hauser Conducta Gesellschaft für Mess- und Regeltechnik mbH + Co. KG Gradiometer for determining the electrical conductivity of a medium contained in a container
WO2014071379A1 (en) * 2012-11-05 2014-05-08 Pronai Therapeutics, Inc. Dosing and administration of oligonucleotide cancer therapies
CN104884637A (en) * 2012-11-05 2015-09-02 普隆奈治疗公司 Methods of using biomarkers for the treatment of cancer by modulation of BCL2 expression
EP2920325A2 (en) * 2012-11-15 2015-09-23 Bristol-Myers Squibb Company Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent
CA3236835A1 (en) 2013-11-22 2015-05-28 Mina Therapeutics Limited C/ebp alpha short activating rna compositions and methods of use
EP3316894A4 (en) * 2015-07-02 2019-06-19 City of Hope Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof

Also Published As

Publication number Publication date
US20210187007A1 (en) 2021-06-24
KR20230156961A (en) 2023-11-15
JP2021192616A (en) 2021-12-23
JP6768701B2 (en) 2020-10-14
JP2018516545A (en) 2018-06-28
JP2024079713A (en) 2024-06-11
CN108291228A (en) 2018-07-17
CN114525279A (en) 2022-05-24
US20200376020A1 (en) 2020-12-03
CA2980975A1 (en) 2016-10-27
US10912790B2 (en) 2021-02-09
AU2019210578B2 (en) 2022-01-13
KR102599712B1 (en) 2023-11-09
JP2021000119A (en) 2021-01-07
AU2019210578A1 (en) 2019-08-22
AU2022202355A1 (en) 2022-04-28
EP3286316A1 (en) 2018-02-28
AU2016251415B9 (en) 2019-05-23
AU2016251415B2 (en) 2019-05-02
JP6931733B2 (en) 2021-09-08
WO2016170349A1 (en) 2016-10-27
KR20170136542A (en) 2017-12-11
AU2016251415A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
SG11201707683YA (en) C/ebp alpha sarna compositions and methods of use
GB2582482B (en) CASZ compositions and methods of use
HK1256608A1 (en) Flavonoid compositions and methods of use
HK1247238B (en) Engineered crispr-cas9 compositions and methods of use
ZA201707981B (en) Compositions of obeticholic acid and methods of use
GB2582100B (en) CAS12C Compositions and methods of use
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
HK1250657A1 (en) High elasticity hyaluronan compositions and methods of use thereof
ZA201906169B (en) Synthekine compositions and methods of use
HUE051713T2 (en) Compositions of selenoorganic compounds and methods of use thereof
HK1243354B (en) Novel iodophor composition and methods of use
HK1251979A1 (en) Peptide compositions and methods of use
IL265761A (en) Terlipressin compositions and their methods of use
HK1247136A1 (en) Compositions comprising 15-hepe and methods of using the same
HK1252057A1 (en) Novel method of use and compositions
HK1250345A1 (en) Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same
HK1231395A1 (en) Bioactive heme-haloperoxidase compositions and methods of their use
EP3253396A4 (en) Probiotic compositions and methods of use
HK1243404A1 (en) Tryptamide compositions and methods of use
GB201511799D0 (en) Composition and methods of treatment
HK1248527A1 (en) Dental compositions and methods of use
IL261794A (en) Compositions and methods of their use
IL247645A0 (en) Compositions of selenoorganic compounds and methods of use thereof